HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Dihydrotachysterol

HCID 5311071
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
67-96-9
Standard SMILES
CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]12C
InChIKey
ILYCWAKSDCYMBB-OPCMSESCSA-N
Molecular formula
C28H46O
Average molar mass
398.7 g/mol
Monoisotopic mass
398.35486609

Overview

Dihydrotachysterol is a hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent. It has a role as a bone density conservation agent. It is a vitamin D, a seco-ergostane and a hydroxy seco-steroid.

Names & identifiers

Preferred name
Dihydrotachysterol
IUPAC
trans-(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
English name
Dihydrotachysterol
Molecular formula
C28H46O
Molecular weight
398.66

Names & synonyms

dihydrotachysterolDichystrolum67-96-9AntitanilHytakerolDihidrotaquisterolDihydrotachysterol2DihydralDygratylParterolTachyrolAnti-tetany substance 10
Show more names
AT-10C06957DygraylHSDB3314dht(sub2)
DihydrotachysterolumDHT2TachystinDiidrotachisteroloDTXSID5022938Dihydrotachysterol 2AT 10Tachysterol, dihydro-

Database identifiers

CAS
67-96-9
PubChem CID
5311071
DTXSID
DTXSID5022938
ChEMBL
CHEMBL2356023
ChEBI
CHEBI:4591
UNII
R5LM3H112R
EC Number
200-672-7
Nikkaji
J1.415J

Properties

Computed structural propertiesFilling in

XLogP
7.7
Topological polar surface area
20.2 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
1
Rotatable bonds
5
Heavy atoms
29
Formal charge
0
Complexity
639

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Secosteroids [ST03] -> Vitamin D2 and derivatives [ST0301]
LogP7.5
OdorODORLESS
Color/Form · 2 items

Needles from 90% methanol

COLORLESS OR WHITE CRYSTALS, OR WHITE, CRYSTALLINE POWDER

Solubility · 3 items

Easily sol in organic solents

SOL IN ALC; FREELY SOL IN ETHER & CHLOROFORM; SPARINGLY SOL IN VEGETABLE OILS

1.25e-04 g/L

Melting Point · 2 items

131 °C

126 °C

Optical Rotation · 2 items

Specific Optical Rotation: +97.5 deg at 22 °C/D (chloroform)

SPECIFIC OPTICAL ROTATION: +100 DEG TO +103 DEG (ALC)

Physical Description

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 3 notifications to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (97.6%)

Safety & protection

Disposal Methods · 1 item

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Toxicology

Treatment · 1 item

Treatment of overdosage consists of withdrawal of dihydrotachysterol, bed rest, liberal intake of fluids, a low-calcium diet, and administration of a laxative. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diurectic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acids), and mithramycin via appropriate regimens. (L1712)

Chemistry & industry

Pharmacology

ATC Code · 2 items

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Bionecessity · 5 items

In children, the result /of deficiency of vitamin D/ is a failure to mineralize newly formed bone and cartilage matrix, causing the defect in growth known as rickets. As a consequence of inadequate calcification, bones of individuals with rickets are soft, and the stress of weight bearing gives rise to characteristic deformities. /Vitamin D/

In adults, vitamin D deficiency results in osteomalacia, a disease characterized by generalized accumulation of underminiralized bone matrix. Severe osteomalacia may be associated with extreme bone pain and tenderness. Muscle weakness, particularly of large proximal muscles, is typical. Its basis is not fully understood but may reflect hypophosphatemia and inadequate vitamin D action on muscle. Gross deformity of bone occurs only in advanced stages of the disease. Circulating 25-OHD (25-hydroxycholecalciferol) concentrations below 8 ng/mL are highly predictive of osteomalacia. /Vitamin D/

The exact physiologic function of vitamin D in brain, heart, pancreas, mononuclear cells, activated lymphocytes, and skin remains unknown, and although the vitamin exhibits potent antiproliferative and prodifferentiation effects, there currently is little evidence that vitamin D deficiency results in major disorders in these organs and cellular systems. The possibility that vitamin D deficiency may be associated with an increased risk of colon, breast, and prostate cancer has been suggested by epidemiologic evidence from individuals living in higher latitudes, but current evidence is too limited to indicate categorically a cancer risk associated with deficiency. /Vitamin D/

Vitamin D deficiency causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus resulting in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism results in porotic bone. /Vitamin D/

Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization. In children, vitamin D deficiency leads to rickets as a result of inadequate mineralization of bone and is characterized by widening of the end of long bones, rachitic rosary, skeletal deformations (e.g., frontal bossing), and outward and inward deformities of the lower limbs resulting in bowed legs and knocked knees, respectively. In adults, vitamin D deficiency leads to a mineralization defect resulting in osteomalacia. /Vitamin D/

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Solid
Collision Cross Section205.8 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

Physicochemical properties

Melting point
116 · 116-120°C
alpha
22 · D22 +97.5° (chloroform)
Boiling point
461.8 °C · 461.8°C (rough estimate)
Density
0.9678 · 0.9678 (rough estimate)
refractive index
1.51 · 1.5100 (estimate)
storage temp.
2 · 2-8°C
solubility
Practically insoluble in water, freely soluble in acetone and hexane, sparingly soluble in ethanol (96 per cent).
pka
14.96 · 14.96±0.40(Predicted)
form
Solid
color
White to off-white
biological source
synthetic
Henry's Law Constant
2.7 · 2.7×10-2 mol/(m3Pa) at 25℃, HSDB (2015)
Stability
Light sensitive
Major Application
food and beverages
InChIKey
ILYCWAKSDCYMBB-KWOSLRGBSA-N
SMILES
C[C@@H]([C@@]1([H])CC[C@@]2([H])/C(CCC[C@@]21C)=C/C=C3[C@@H](C)CC[C@H](O)C/3)/C=C/[C@H](C)C(C)C
FDA UNII
5 LM3H112R · R5LM3H112R
ATC code
11 CC02 · A11CC02
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301-H413
Precautionary statements
264 · P264-P270-P273-P301+P310-P405-P501
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xn
Risk Statements
22 · 22
Safety Statements
36 · 36
RIDADR
2811 · UN 2811 6.1/PG 3
WGK Germany
3 · 3
RTECS
600000 · WW0600000
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2936299055 · 2936299055
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralAquatic · Acute Tox. 3 OralAquatic Chronic 4
Hazardous Substances Data
67 · 67-96-9(Hazardous Substances Data)
Toxicity
50 oral · LD50 oral in mouse: 288mg/kg
Interactions · 5 items

Corticosteroids counteract the effects of vitamin D analogs. /Vitamin D analogs/

Concurrent administration of thiazide diuretics and pharmacologic doses of vitamin D analogs in patients with hypoparathyroidism may result in hypercalcemia which may be transient and self-limited or may require discontinuance of vitamin D analogs. Thiazide-induced hypercalcemia in hypoparathyroid patients is probably caused by increased release of calcium from bone. /Vitamin D analogs/

Excessive use of mineral oil may interfere with intestinal absorption of vitamin D analogs. /Vitamin D analogs/

Orlistat may result in decreased GI absorption of fat-soluble vitamins such as vitamin D analogs. At least 2 hours should elapse between (before or after) any orlistat dose and vitamin D analog administration ... . /Vitamin D analogs/

For more Interactions (Complete) data for DIHYDROTACHYSTEROL (6 total), please visit the HSDB record page.

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 2.5X10+6(SRC), determined from a structure estimation method(2), indicates that dihydrotachysterol is expected to be immobile in soil(SRC). Volatilization of dihydrotachysterol from moist soil surfaces may occur(SRC) given an estimated Henry's Law constant of 3.7X10-4 atm-cu m/mole(SRC), using a fragment constant estimation method(3). However, adsorption to soil is expected to attenuate volatilization(SRC). Dihydrotachysterol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.2X10-10 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2006).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 2.5X10+6(SRC), determined from a structure estimation method(2), indicates that dihydrotachysterol is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces may occur(3) based upon an estimated Henry's Law constant of 3.7X10-4 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 5 hours and 9 days, respectively(SRC). However, volatilization from water surfaces is expected to be attenuated by adsorption to suspended solids and sediment in the water column(SRC). The volatilization half-life from a model pond is about 5.3X10+5 years when adsorption is considered(5). According to a classification scheme(6), an estimated BCF of 3.2(SRC), from an estimated log Kow of 10(7) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2006).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dihydrotachysterol, which has an estimated vapor pressure of 5.2X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase dihydrotachysterol may be removed from the air by wet or dry deposition(SRC). Dihydrotachysterol does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Exposure RoutesOral
Toxicity Summary · 1 item

Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor)stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone.

Signs and SymptomsToxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D.
Soil Adsorption/Mobility · 1 item

Using a structure estimation method based on molecular connectivity indices(1), the Koc of dihydrotachysterol can be estimated to be 2.5X10+6(SRC). According to a classification scheme(2), this estimated Koc value suggests that dihydrotachysterol is expected to be immobile in soil.

Human Toxicity Excerpts · 5 items

/SIGNS AND SYMPTOMS/ Adverse effects result mainly from hypercalcemia. They include anorexia ... languor ... weight loss, metastatic calcification, renal damage, anemia, band keratitis, and convulsions. In severe hypercalcemia there may be ... vertigo, tinnitus, abdominal cramps ... thirst, ataxia, albuminuria, and xanthemia.

/SIGNS AND SYMPTOMS/ The initial signs and symptoms of vitamin D toxicity are those associated with hypercalcemia. ... Hypercalcemia with hypervitaminosis D is due generally to very high circulating levels or 25-OHD (25-hydroxycholecalciferol), and plasma concentrations of PTH (parathyroid hormone) and calcitriol are typically but not uniformly suppressed. /Vitamin D/

/SIGNS AND SYMPTOMS/ In children, a single episode of moderately severe hypercalcemia /caused by vitamin D toxicity/ may arrest growth completely for 6 months or more, and the deficit in height may never be fully corrected. /Vitamin D/

/SIGNS AND SYMPTOMS/ Vitamin D toxicity may be manifested in the fetus. There is a relationship between excess maternal vitamin D intake or extreme sensitivity and nonfamilial congenital supravalvular aortic stenosis. In infants, this anomaly is often associated with other stigmata of hypercalcemia. Maternal hypercalcemia also may result in suppression of parathyroid function in the newborn, with resultant hypocalcemia, tetany, and seizures. /Vitamin D/

For more Human Toxicity Excerpts (Complete) data for DIHYDROTACHYSTEROL (6 total), please visit the HSDB record page.

Artificial Pollution SourcesDihydrotachysterol's production and use for the treatment of hypocalcemic tetany(1) may result in its release to the environment through various waste streams(SRC).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Environmental Bioconcentration · 1 item

An estimated BCF of 3.2 was calculated for dihydrotachysterol(SRC), using an estimated log Kow of 10(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The Henry's Law constant for dihydrotachysterol is estimated as 3.7X10-4 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that dihydrotachysterol may volatilize from water surfaces(2). Based on this Henry's Law constant, the volatilization half-life from a model river (1 m deep, flowing 1 m/sec, wind velocity of 3 m/sec)(2) is estimated as 5 hours(SRC). The volatilization half-life from a model lake (1 m deep, flowing 0.05 m/sec, wind velocity of 0.5 m/sec)(2) is estimated as 9 days(SRC). However, volatilization from water surfaces is expected to be attenuated by adsorption to suspended solids and sediment in the water column(SRC). The volatilization half-life from a model pond is about 5.3X10+5 years when adsorption is considered(3). Dihydrotachysterol's Henry's Law constant indicates that volatilization from moist soil surfaces may occur(SRC). However, adsorption to soil is expected to attenuate volatilization(SRC). Dihydrotachysterol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.2X10-10 mm Hg(SRC), determined from a fragment constant method(4).

Safety data

PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
wgk
3
rtecs
WW0600000
ridadr
UN 2811 6.1/PG 3
hs_code
2936299055
Toxicity
LD50 oral in mouse: 288mg/kg
risk_code
22
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
Xn
safety_code
36
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301-H413
Hazard Classifications
Acute Tox. 3 OralAquatic Chronic 4
Precautionary statements
P264-P270-P273-P301+P310-P405-P501
Hazardous Substances Data
67-96-9(Hazardous Substances Data)
Protein Binding>99%
Pharmacodynamics · 1 item

Dihydrotachysterol is hydroxylated in the liver to 25-hydroxydihydrotachysterol, which is the major circulating active form of the drug. It does not undergo further hydroxylation by the kidney and therefore is the analogue of 1, 25-dihydroxyvitamin D. Dihydrotachysterol is effective in the elevation of serum calcium by stimulating intestinal calcium absorption and mobilizing bone calcium in the absence of parathyroid hormone and of functioning renal tissue. Dihydrotachysterol also increases renal phosphate excretion.

Mechanism of Action · 2 items

Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor)stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone.

Elevates serum calcium concentration by increasing intestinal absorption of calcium & possibly by enhancing urinary excretion of inorganic phosphate... /drug-induced/ phosphaturia may be ... due to increased serum calcium level and its effect on phosphate clearance by kidneys.

Biological Half-Life · 1 item

Absorbed vitamin D circulates in blood in association with vitamin D-binding protein, which is a specific alpha-globulin. Vitamin D disappears from plasma with /a half-life/ of 19 to 25 hr, but it is stored in body for prolonged periods (6 months or longer in rat) apparently in fat deposits throughout body. /Vitamin D/

Metabolism/Metabolites · 2 items

DHT3 /vitamin D3/ undergoes 25-hydroxylation to yield 25-hydroxydihydrotachysterol3 (25-OHDHT3), which appears to be active form of DHT (dihydrotachysterol) in both intestine & bone.

High specific radioactivity (14)C- and (3)H-labeled dihydrotachysterol were prepared and their metabolites studied in rachitic chicks and rats. 20% dihydrotachysterol was excreted in the bile in the first 24 hours, about 50% as a carboxylic acid derivative. No hydroxylation at C-1 was observed, although polar metabolites were detected in all tissues. Larger proportions of the parent steroid and its 25-OH derivative were detected in tissues compared with cholecalciferol but no single metabolite was detected at the intracellular site of action of cholecalciferol.

MeSH Pharmacological Classification · 2 items

Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Absorption, Distribution and Excretion · 5 items

Onset of action: Hypercalcemic: Several hours (maximal after 1 to 2 weeks).

...Major path of elimination of dihydrotachysterol & its metabolites is probably secretion into bile & excretion in feces ... dihydrotachysterol /is also/ excreted in breast milk ...

Duration of action: following oral administration: Up to 9 weeks.

The primary route of excretion of vitamin D is the bile; only a small percentage of an administered dose is found in urine. /Vitamin D/

For more Absorption, Distribution and Excretion (Complete) data for DIHYDROTACHYSTEROL (8 total), please visit the HSDB record page.

Cellular LocationsCytoplasm

Uses & manufacturing

Uses · 5 items

Treatment of hypocalcemic tetany

MEDICATION

MEDICATION (VET)

Bone Density Conservation Agents; Vitamins

Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).

Methods of Manufacturing · 3 items

...Reduction of tachysterol

v. Werder, US PATENT 2228491 (1941 TO Winthrop)

Calciferol (activated ergosterol) is dissolved in suitable organic solvent & subjected to catalytic hydrogenation until proper amount of hydrogen has reacted.

Formulations/PreparationsOral: Capsules 0.125 mg Hytakerol, (Sanofi-Aventis); Solution, concentrate: 0.2 mg/mL DHT Intensol (with alcohol 20%), (Roxane).
General Manufacturing Information · 3 items

USP unit is identical with international unit & is equivalent to specific biological activity of 0.025 ug of vitamin D3 (ie 1 mg equals 40,000 units). /Vitamin D/

Dihydrotachysterol (DHT) is analog of vitamin D that may be regarded as reduction product of either vitamin D2 (DHT2) or vitamin D3 (DHT3). DHT is about 1/450 as active as vitamin D in usual antirachitic assay, but at high doses it is much more effective than high doses of vitamin D in mobilizing calcium from bone.

Dihydrotachysterol or vitamin D2, both at 10-50 mg/L, increased production of adventitious roots in herbaceous cuttings of populus tremula (aspen) by approximately 60 and 100%, respectively.

Applications · 3 items

DescriptionDihydrotachysterol is a synthetic analog of vitamin D. It is considered as a reduction product of vitamin D2 (ergocalciferol). It stimulates bone mineralization as well as calcium and phosphorus absorption in intestine. Dihydrotachysterol has been used for the treatment of hypoparathyroidism, osteomalacia, osteoporosis, low calcium level, and kidney osteodystrophy. Though dihydrotachysterol is more expensive, dihydrotychysterol therapy is preferred as it has a more rapid onset of action (1-7 d) and a shorter time for dissipation of effect in the event of toxicity (2-3 weeks) than vitamin D2.

UsesDihydrotachysterol is a form of vitamin D. Vitamin D is a fat-soluble vitamin and has properties of both vitamins and minerals. Vitamin D helps you to absorb calcium from what you eat. You need calcium to keep your bones strong, and to help your muscles and nerves work properly. The term Vitamin D collectively refers to a group of structurally similar chemicals and their metabolites, which includes alfacalcidol (1 α hydroxycholecalciferol), calcitriol (1,25-dihydroxychole-calciferol), cholecalciferol (Vitamin D3), dihydrotachysterol(DHT) and ergocalciferol (Vitamin D2). These agents have antirachitic properties. Dihydrotachysterol-2 (DHT-2) is a vitamin D2 analog for the Pharmaceutical industry. Dihydrotachysterol-2 is used in the prevention and treatment of several bone growth disorders such as osteoporosis. Besides this the substance is also used to treat several abnormalities of the parathyroid glands such as hypoprathyroidism.

UsesCalcium regulator. Preparation by reduction of Tachysterol. It is widely used for hypocalcemic hypoparathyroidism following surgical removal of parathyroids.

Upstream & downstream products

Upstream raw materials

(6E,22E)-(3R)-9,10-secoergosta-5(10),6,8,22-tetraen-3-olHydrogen

Additional notes

DefinitionChEBI: A hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent.